Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine

Andrew T. Catanzaro, Mario Roederer, Richard A. Koup, Robert T. Bailer, Mary E. Enama, Martha C. Nason, Julie E. Martin, Steve Rucker, Charla A. Andrews, Phillip L. Gomez, John R. Mascola, Gary J. Nabel, Barney S. Graham

Research output: Contribution to journalArticlepeer-review


Needle-free delivery of a six-plasmid HIV-1 DNA vaccine encoding EnvA, EnvB, EnvC, and subtype B Gag, Pol, and Nef underwent open-label evaluation in 15 subjects; 14 completed the 0, 1, 2 month vaccination schedule. T cell responses to HIV-specific peptide pools were detected by intracellular cytokine staining of CD4+ [13/14 (93%)] and CD8+ [5/14 (36%)], and by ELISpot in 11/14 (79%). Ten of 14 (71%) had ELISA antibody responses to Env proteins. Compared to a four-plasmid product, Gag- and Nef-specific T cell responses were improved, while Env-specific responses were maintained. This candidate vaccine has now advanced to Phase II evaluation.

Original languageEnglish (US)
Pages (from-to)4085-4092
Number of pages8
Issue number20
StatePublished - May 16 2007
Externally publishedYes


  • AIDS
  • Envelope
  • Gag
  • Nef
  • Pol
  • Prevention
  • Promoter
  • T cell response

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)


Dive into the research topics of 'Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine'. Together they form a unique fingerprint.

Cite this